Switzerland's Kuros Biosciences 2025 total medical device revenue rises, helped by MagnetOs growth

Reuters03-10
Switzerland's Kuros Biosciences 2025 total medical device revenue rises, helped by MagnetOs growth

Overview

  • Switzerland's bone healing tech firm reported 72% total medical device revenue growth in 2025

  • Company achieved first-ever net profit of USD 2.6 million

  • Company expects at least 35% sales growth in 2026

Outlook

  • Kuros expects at least 35% sales growth in 2026 with adjusted EBITDA margin around 14%

  • Company anticipates 2028 sales of USD 300 to 330 mln with adjusted EBITDA margin of 20%

  • Kuros sees growth driven by MagnetOs adoption and market penetration in U.S. and Europe

Result Drivers

  • MAGNETOS SALES - Direct MagnetOs sales rose by 71% to USD 143.9 mln, significantly contributing to overall revenue growth

  • MARKET EXPANSION - Kuros expanded into the extremities market, supported by a dedicated commercial team and clinical trials

  • NEW PRODUCT LAUNCHES - FDA clearance and launch of MagnetOs MIS Delivery System supported minimally invasive surgeries

Company press release: ID:nGNX3zFzYw

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

FY Total Medical Device Revenue

$146.06 mln

FY Operating Income

$8.95 mln

Analyst Coverage

  • The one available analyst rating on the shares is "strong buy"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy."

  • Wall Street's median 12-month price target for Kuros Biosciences AG is CHF36.50, about 37.3% above its March 9 closing price of CHF26.58

  • The stock recently traded at 78 times the next 12-month earnings vs. a P/E of 95 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment